Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006

Inflammatory Bowel Diseases

Volumn 17, Issue 12, 2011, Pages 2558-2565

  Lakatos, Laszlo ^a   Kiss, Lajos S ^b   David, Gyula ^a   Pandur, Tunde ^a   Erdelyi, Zsuzsanna ^a   Mester, Gabor ^c   Balogh, Mihaly ^c   Szipocs, Istvan ^d   Molnar, Csaba ^e   Komaromi, Erzsebet ^d   Laszlo Lakatos, Peter ^b  

^a Csolnoky F Province Hospital   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Grof Eszterhazy Hospital   (Hungary)

^d Municipal Hospital   (Hungary)

^e Magyar Imre Hospital   (Hungary)

Author keywords

CD; disease course; incidence; UC

Indexed keywords

AZATHIOPRINE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ADULT; ARTICLE; COLITIS; COLON RESECTION; CROHN DISEASE; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUNGARY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HUNGARY; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHENOTYPE; PREVALENCE; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 80855133542     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21607     Document Type: Article

References (29)

1. Lakatos PL,. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006; 12: 6102-6108. (Pubitemid 44688157)
2. Loftus EV,. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504-1517.
3. Loftus CG, Loftus EV Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis. 2007; 13: 254-261. (Pubitemid 46465905)
4. Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut. 1996; 39: 690-697. (Pubitemid 26426470)
5. Lakatos L, Lakatos PL,. Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J. 2006; 82: 332-337. (Pubitemid 43780664)
6. Ouyang Q, Tandon R, Goh KL, et al. The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol. 2005; 21: 408-413. (Pubitemid 40961165)
7. Munkholm P, Langholz E, Nielsen OH, et al. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992; 27: 609-614.
8. Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006; 101: 1274-1282. (Pubitemid 43833122)
9. Lakatos L, Mester G, Erdelyi Z, et al. Striking elevation in the incidence and prevalence of inflammatory bowel disease in a province of Western Hungary between 1977-2001. World J Gastroenterol. 2004; 10: 404-409. (Pubitemid 38208096)
10. Mijandrusic-Sincic B, Vucelic B, Persic M, et al. Incidence of inflammatory bowel disease in Primorsko-Goranska county, Croatia, 2000-2004. Scand J Gastroenterol. 2006; 41: 437-444. (Pubitemid 43675410)
11. Pavlovic-Calic N, Salkic NN, Gegic A, et al. Crohn's disease in Tuzla region of Bosnia and Herzegovina: a 12-year study (1995-2006). Int J Colorectal Dis. 2008; 23: 957-964.
12. Salkic NN, Pavlovic-Calic N, Gegic A, et al. Ulcerative colitis in the Tuzla region of Bosnia and Herzegovina between 1995 and 2006: epidemiological and clinical characteristics. Eur J Gastroenterol Hepatol. 2010; 22: 346-353.
13. Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn disease. Gastroenterology. 2006; 130: 650-656.
14. Lennard-Jones JE,. Classification of inflammatory bowel disease. Scand J Gastroenterol. 1989; 24 (suppl 170): 2-6. (Pubitemid 20015811)
15. Lakatos L, Pandur T, David G, et al. Association of extraintestinal manifestations of inflammatory bowel disease (IBD) in a province of Western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol. 2003; 9: 2300-2307. (Pubitemid 37321464)
16. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (suppl i): i1-i15. (Pubitemid 43268290)
17. Stange EF, Travis SP, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn Colitis. 2008; 2: 1-23. (Pubitemid 351179487)
18. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (suppl A): 5-36.
19. Stowe SP, Redmond SR, Stormont JM, et al. An epidemiological study of inflammatory bowel disease in Rochester, New York. Hospital incidence. Gastroenterology. 1990; 98; 104-110 (Pubitemid 20017790)
20. Solberg IC, Vatn MH, He O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5: 1430-1438. (Pubitemid 350181602)
21. Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut. 2006; 55: 1124-1130 (Pubitemid 44085679)
22. Thia KT, Sandborn WJ, Harmsen WS, et al. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010; 139: 1147-1155.
23. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Early Crohn disease: a proposed definition for use in disease-modification trials. Gut. 2010; 59: 141-147.
24. Lakatos PL, Czegledi Z, Szamosi T, et al. Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease. World J Gastroenterol. 2009; 15: 3504-3510.
25. Szamosi T, Banai J, Lakatos L, et al. Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis. Eur J Gastroenterol Hepatol. 2010; 22: 872-879.
26. Wolters FL, Joling C, Russel MG, et al. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol. 2007; 42: 333-344.
27. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. 2007; 13: 481-489 (Pubitemid 46668255)
28. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44: 431-440.
29. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007; 132: 507-515.